VYZULTA: Available in Pharmacies Nationwide.

VYZULTA achieved the primary objective:
noninferiority to timolol 0.5% at all tested time points1,2

Mean IOP reduction of 7.5 to 9.1 mmHg from baseline with VYZULTA3

VYZULTA demonstrated superior IOP reduction vs timolol 0.5% at Month 33

In APOLLO, baseline mean diurnal IOP was 26.7 mmHg and 26.5 mmHg in patients randomized to VYZULTA and timolol 0.5%, respectively1

Apollo Study Chart

Please swipe to see more data

In LUNAR, baseline mean diurnal IOP was 26.6 mmHg and 26.4 mmHg in patients randomized to VYZULTA and timolol 0.5%, respectively2

Lunar Study Chart

Please swipe to see more data

VYZULTA (LBN 0.024%) demonstrated statistically significant greater mean IOP reduction compared with XALATAN (latanoprost) 0.005% at Day 285

In the VOYAGER dose-ranging study, VYZULTA (LBN 0.024%) lowered mean diurnal IOP by 1.23 mmHg more than XALATAN (latanoprost) 0.005% at day 285

IOP reduction from baseline at Day 28:

VYZULTA (LBN 0.024%) = 34.6%

XALATAN (latanoprost) 0.005% = 29.8%


Baseline mean diurnal IOP:

VYZULTA (LBN 0.024%) = 26.01 mmHg

XALATAN (latanoprost) 0.005% = 26.15 mmHg

Voyager study design voyager study design
Voyager study design

VYZULTA achieved long-term IOP reduction in patients with low baseline IOP6

In the long-term JUPITER study, treatment with VYZULTA resulted in a statistically significant reduced mean IOP of 14.4 mmHg at 12 months6

VYZULTA IOP reduction from baseline

26.5%

Majority of patients had baseline IOP ≤21.0 mmHg

P <0.001 at all measurements

Jupiter study design jupiter study design
Jupiter study design

VYZULTA has a demonstrated safety profile

Less than 1% discontinuation due to ocular adverse reactions1

Approximately 0.6% of patients discontinued VYZULTA therapy due to ocular adverse reactions

The most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)3

To receive updates and learn more about VYZULTA, please complete the form below.

Loading...

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
1. Weinreb RN, Sforzolini BS, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973.
2. Medeiros FA, Martin KR, Peace J, Sforzolini BS, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259.
3. VYZULTA Prescribing Information. Bausch & Lomb Incorporated. 2017.
4. Data on File. Bausch & Lomb Incorporated.
5. Weinreb RN, Ong T, Scassellati SB, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745.
6. Kawase K, Vittitow JL, Weinreb RN, Araie M. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612-1627.

See Less

See More

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
1. Weinreb RN, Sforzolini BS, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973.
2. Medeiros FA, Martin KR, Peace J, Sforzolini BS, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259.
3. VYZULTA Prescribing Information. Bausch & Lomb Incorporated. 2017.
4. Data on File. Bausch & Lomb Incorporated.
5. Weinreb RN, Ong T, Scassellati SB, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745.
6. Kawase K, Vittitow JL, Weinreb RN, Araie M. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612-1627.